After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

Shares of Gilead Sciences Inc. slid 4.80% to $97.88 Tuesday, on what proved to be an all-around poor trading session for the ...

Gilead Sciences Down Nearly 5%, On Track for Largest Percent Decrease Since January 2024 — Data Talk Gilead Sciences, Inc. (GILD) is currently at $97.68, down $5.14 or 4.99% --Would be lowest close ...

On April 29, 2025, the U.S. Attorney’s Office for the Southern District of New York (SDNY) announced a $202 million civil False Claims Act ...

As it applies to the development of cell therapies, AstraZeneca’s chief of global operations, Pam Cheng, admits that the ...

Gilead is a vast pharmaceutical multinational. With a $175 billion market capitalisation nothing about the company is going to be small. There's a large HIV treatment arm which gives it a base in ...

The pharma industry’s reputation dropped slightly again among patient groups, largely due to drug pricing issues.

Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.

Biotechs such as Gilead (NASDAQ:GILD) and Vertex Pharma (NASDAQ:VRTX), with a high local tax bill, a heavy U.S.-based ...

Shares of Gilead Sciences Inc. GILD slid 3.09% to $103.25 Thursday, on what proved to be an all-around favorable trading ...

Here are 10 recent healthcare industry lawsuits, settlements and legal developments that Becker's has reported since April 22: ...

Gilead Sciences has agreed to pay $202 million to resolve allegations that it violated the Anti-Kickback Statute by using speaker programs to incentivize physicians to prescribe HIV medications.